Insilico Medicine's rentosertib shows promise in a clinical trial for idiopathic pulmonary fibrosis, making patients appear biologically 3-4 years younger. While the findings are intriguing, they do not yet support its use as an anti-aging treatment.
Rentosertib, a drug developed by Insilico Medicine for idiopathic pulmonary fibrosis, made patients appear biologically younger in a clinical trial using aging clocks. Rentosertib, an AI-discovered drug for idiopathic pulmonary fibrosis, made patients appear three to four years biologically younger in a clinical trial. A drug being developed to treat a serious lung disease may also help to slow the aging process, researchers say. In a small clinical study, patients who took rentosertib – developed by Insilico Medicine in Massachusetts – showed changes in blood proteins that made them appear biologically younger. Several tests estimated that after treatment, the patients were biologically about three to four years younger. The results were based only on changes in proteins in their blood, and do not yet support the use of rentosertib as an anti-aging treatment. The risks and side effects associated with rentosertib were found to be "manageable," according to Dr. Carol Ann Satler, senior vice president of clinical development for Insilico Medicine. This means it’s possible that the improvements in the participants’ lung disease was related to the changes in blood proteins. Larger and longer trials – including healthy older adults and populations without IPF – are needed to determine whether the drug truly has anti-aging effects and whether they could lead to better health.
Original title: “Experimental lung disease drug may slow aging by 3-4 years, study suggests | Fox News”